Hyloris Pharmaceuticals Financial Health
Financial Health criteria checks 6/6
Hyloris Pharmaceuticals has a total shareholder equity of €48.7M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €57.3M and €8.6M respectively.
Debt to equity ratio
|Interest coverage ratio||n/a|
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: HYL's short term assets (€45.0M) exceed its short term liabilities (€6.7M).
Long Term Liabilities: HYL's short term assets (€45.0M) exceed its long term liabilities (€1.8M).
Debt to Equity History and Analysis
Debt Level: HYL is debt free.
Reducing Debt: HYL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HYL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HYL has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 20.4% each year.